Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

BUY
$33.06 - $39.43 $12.8 Million - $15.3 Million
388,360 New
388,360 $15.3 Million
Q3 2022

Nov 14, 2022

SELL
$30.79 - $39.82 $3.87 Million - $5 Million
-125,542 Reduced 22.29%
437,645 $15.8 Million
Q2 2022

Aug 15, 2022

SELL
$25.44 - $35.16 $407,574 - $563,298
-16,021 Reduced 2.77%
563,187 $17.1 Million
Q1 2022

May 11, 2022

SELL
$25.09 - $33.13 $5.33 Million - $7.03 Million
-212,317 Reduced 26.82%
579,208 $17.7 Million
Q4 2021

Feb 11, 2022

SELL
$15.6 - $35.4 $2.23 Million - $5.07 Million
-143,118 Reduced 15.31%
791,525 $24.7 Million
Q3 2021

Nov 12, 2021

SELL
$14.86 - $19.45 $13,359 - $17,485
-899 Reduced 0.1%
934,643 $14.3 Million
Q2 2021

Aug 11, 2021

SELL
$16.81 - $20.0 $380,090 - $452,220
-22,611 Reduced 2.36%
935,542 $17.4 Million
Q1 2021

May 13, 2021

BUY
$13.65 - $21.31 $121,689 - $189,978
8,915 Added 0.94%
958,153 $17.2 Million
Q4 2020

Feb 09, 2021

BUY
$9.49 - $16.04 $1.92 Million - $3.25 Million
202,435 Added 27.11%
949,238 $14.6 Million
Q3 2020

Nov 12, 2020

SELL
$10.82 - $13.35 $518,126 - $639,278
-47,886 Reduced 6.03%
746,803 $8.27 Million
Q2 2020

Aug 12, 2020

BUY
$10.21 - $14.9 $1.21 Million - $1.77 Million
118,813 Added 17.58%
794,689 $9.97 Million
Q1 2020

May 06, 2020

BUY
$8.08 - $17.57 $3.47 Million - $7.55 Million
429,613 Added 174.45%
675,876 $7.66 Million
Q4 2019

Feb 14, 2020

SELL
$8.11 - $14.65 $32,334 - $58,409
-3,987 Reduced 1.59%
246,263 $3.23 Million
Q3 2019

Nov 07, 2019

BUY
$8.74 - $10.51 $198,494 - $238,692
22,711 Added 9.98%
250,250 $2.25 Million
Q2 2019

Aug 12, 2019

BUY
$8.51 - $10.75 $1.94 Million - $2.45 Million
227,539 New
227,539 $2.24 Million

Others Institutions Holding XENE

About Xenon Pharmaceuticals Inc.


  • Ticker XENE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,263,500
  • Market Cap $2.39B
  • Description
  • Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...
More about XENE
Track This Portfolio

Track Bank Of New York Mellon Corp Portfolio

Follow Bank Of New York Mellon Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

News

Stay updated on Bank Of New York Mellon Corp with notifications on news.